Statistics on Biotechnology Use  
Results by sector of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total;
No. of companies carrying out R&D in Biotechnology;1.010;69;1.078;
%Companies according to biotechnology used: Genetic code;34;49;35;
%Companies according to biotechnology used: Functional units;41;54;42;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;25;48;27;
%Companies according to biotechnology used: Bioprocesses;48;59;49;
%Companies according to biotechnology used: Sub-cellular organisms;7;12;8;
%Companies according to biotechnology used: Bio-computing;22;22;22;
%Companies according to biotechnology used: Nanobiotechnology;14;18;14;
%Companies according to biotechnology used: Other;12;8;12;
Companies in which biotechnology activities are: Main and/or exclusive;511;15;526;
Companies in which biotechnology activities are: A secondary line of business;155;18;173;
Companies in which biotechnology activities are: A tool necessary for production;344;35;379;
%Company by field(s) of ultimate application of biotechnology use: Human Health;48;50;48;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;21;5;20;
%Company by field(s) of ultimate application of biotechnology use: Food products;32;36;33;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;24;21;24;
%Company by field(s) of ultimate application of biotechnology use: Environment;15;15;15;
%Company by field(s) of ultimate application of biotechnology use: Industry;14;6;14;
Personnel in R&D in biotechnology (no. of persons);7.849;2.342;10.191;
Personnel in R&D in biotechnology (no. of persons): Researchers;4.469;1.305;5.774;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;3.380;1.037;4.417;
Personnel in R&D in biotechnology (no. of persons): women;4.199;1.326;5.525;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.320;695;3.015;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;1.879;631;2.511;
Personnel in R&D in biotechnology (FTE);5.530,1;1.661,2;7.191,4;
Personnel in R&D in biotechnology (FTE): Researchers;3.333;943,6;4.276,6;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.197,1;717,6;2.914,7;
Personnel in R&D in biotechnology (FTE): women;3.061;924,4;3.985,4;
Personnel in R&D in biotechnology (FTE): (women) Researchers;1.742,1;491,9;2.234;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.318,9;432,5;1.751,4;
Internal expenditure on R&D (thousands of euros);441.736;136.435;578.171;
1) By nature of the expense: Current expenses;387.035;130.565;517.601;
1.1) Remuneration to researchers;158.420;55.335;213.755;
1.2) Remuneration to technicians and assistants;74.027;24.413;98.440;
1.3) Other current expenses;154.588;50.818;205.406;
2) By nature of the expense: Capital expenses;54.701;5.870;60.570;
2.1) Land and buildings;22.554;54;22.609;
2.2) Equipment and instruments;30.685;5.483;36.169;
2.3) Acquisition of specific R&D software;1.461;332;1.793;
1) By origin of the funds: National funds;379.550;108.064;487.615;
1.1) Own funds;249.390;81.068;330.459;
1.2) From companies;32.831;12.630;45.462;
1.3) Public Administration funds;53.162;13.028;66.189;
1.4) From Universities;25.148;.;25.148;
1.5) From non profit private institutions;19.019;1.338;20.357;
1) By origin of the funds: Foreign funds;62.186;28.371;90.556;
2.1) From EU programmes;18.782;2.150;20.932;
2.2) Other foreign funds;43.403;26.221;69.624;
Purchase of R&D services in biotechnology (thousands of euros);111.514;54.508;166.022;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;67.448;30.007;97.455;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;44.065;24.501;68.567;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;47;30;46;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13;12;13;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;14;16;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;14;13;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;18;14;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;17;12;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;18;17;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;35;36;35;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;50;34;49;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;22;9;21;
% Companies that have requested biotechnology patents in Biotechnology;15;21;15;
Number of patents requested;451;75;526;
% Companies with income of an international origin related to biotechnological activities;26,4;19,1;26;
% Turnover representing income of an international origin related to biotechnological activities;6,5;0,8;1,4;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;51,6;76,3;63,8;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;48,4;23,7;36,2;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;85,6;97,7;91,6;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;1,4;0,5;0,9;
% Income of an international origin related with activities according to the classification: Operating source abroad;3;0,7;1,9;
% Income of an international origin related with activities according to the classification: Other;10,1;1,1;5,6;
Notas:

.
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute